国产瓣膜TAVR治疗重度狭窄二叶式主动脉瓣的安全性与有效性评价
本研究为前瞻性单中心非随机对照研究,连续纳入100例使用国产瓣膜行TAVR的症状性重度主动脉瓣狭窄患者,按瓣叶形态分为BAV组51例与TAV组49例,主要终点为术后1个月全因死亡率。结果显示两组器械成功率、瓣中瓣植入率、中重度瓣周漏发生率及1个月全因死亡率差异均无统计学意义,BAV组术后平均跨瓣压差较高但压差下降值与TAV组相似,提示国产瓣膜TAVR治疗BAV重度狭窄具有良好的安全性和有效性。
要点
- BAV组与TAV组器械成功率分别为82.4%与81.6%,差异无统计学意义
- 两组术后1个月全因死亡率分别为2.0%与10.2%,差异无统计学意义
- BAV组术后平均跨瓣压差较高,但较术前下降值与TAV组相似
核心结论
- 使用国产瓣膜行TAVR治疗BAV重度狭窄具有良好的安全性和有效性。
研究设计与样本
- 本研究为前瞻性、单中心、非随机对照研究。
- 连续入选2016年1月至2020年4月在空军军医大学第一附属医院心内科使用国产瓣膜行TAVR的症状性重度AS患者。
- 共纳入100例患者,年龄(69.8±8.9)岁,男性71例(71%),按瓣叶形态分为BAV组51例与TAV组49例。
- 主要终点为术后1个月的全因死亡率。
主要发现
- 与TAV组比较,BAV组年龄较小[(67.1±8.6)岁比(72.7±8.4)岁,P=0.002],近端升主动脉直径较宽[(39.7±5.7)mm比(36.0±4.2)mm,P<0.001],STS-PROM评分较低[3.1(1.9,5.4)%比5.9(2.6,12.3)%,P=0.002]。
- BAV组与TAV组植入瓣中瓣的比例分别为15.7%(8/51)与18.4%(9/49)(P=0.721)。
- BAV组与TAV组中重度瓣周漏发生率分别为2.0%(1/51)与0(P=1.000)。
- BAV组与TAV组器械成功率分别为82.4%(42/51)与81.6%(40/49)(P=0.925)。
- BAV组与TAV组术后1个月全因死亡率分别为2.0%(1/51)与10.2%(5/49)(P=0.108)。
关键数值与推荐
- BAV组术后平均跨瓣压差高于TAV组[13.0(10.0,16.0)mmHg比9.0(7.0,14.0)mmHg,P=0.003](1 mmHg=0.133 kPa)。
- PGmean下降值(较术前)两组差异无统计学意义[(36.7±16.6)mmHg比(36.2±17.5)mmHg,P=0.893]。
临床怎么用
- 对于重度狭窄的BAV患者,使用国产瓣膜行TAVR可作为可选治疗策略,其安全性和有效性在本研究人群中得到验证。
- BAV患者术后平均跨瓣压差较高,但压差下降幅度与TAV患者相似,术后需关注跨瓣压差变化。
局限性
- 本研究为单中心、非随机对照研究,样本量有限。
- 主要终点术后1个月全因死亡率两组差异无统计学意义,需更大样本进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) with domestic prostheses in patients with severely stenotic bicuspid aortic valve (BAV). Methods: This study was a prospective single-center non-randomized controlled study. Patients with symptomatic severe aortic stenosis (AS), who underwent TAVR with domestic prostheses at the First Affiliated Hospital of Air Force Medical University from January 2016 to April 2020 were consecutively included in our study. Patients were divided into BAV group and tricuspid aortic valve (TAV) group according to the aortic valve morphology. Baseline characteristics, procedural outcomes were compared between the two groups, and the primary endpoint was one-month all-cause mortality. Results: A total of 100 patients aged (69.8±8.9) years were enrolled, including 71 (71%) males. There were 51 cases in BAV group and 49 cases in TAV group. Compared with TAV group, patient in the BAV group was younger ((67.1±8.6) years vs. (72.7±8.4) years, P=0.002) and had larger ascending aortic diameter at proximal part ((39.7±5.7) mm vs. (36.0±4.2) mm, P<0.001), lower Society of Thoracic Surgeons-Predicted Risk of Mortality (STS-PROM) score (3.1 (1.9, 5.4) % vs. 5.9 (2.6, 12.3) %, P=0.002). In BAV group and TAV group, the incidence of 2nd prosthesis implantation was 15.7% (8/51) and 18.4% (9/49) (P=0.721), the incidence of moderate or severe paravalvular regurgitation was 2.0% (1/51) and 0 (P=1.000), the rate of device success was 82.4% (42/51) and 81.6% (40/49) (P=0.925), respectively. One-month all-cause mortality was 2.0% (1/51) and 10.2% (5/49) (P=0.108), respectively. Echocardiography showed that postprocedural mean pressure gradient (PGmean) was higher in the BAV group (13.0 (10.0, 16.0) mmHg vs. 9.0 (7.0, 14.0) mmHg, P=0.003) (1 mmHg=0.133 kPa), but the PGmean decrease post procedure as compared with that before TAVR was similar between the two groups ((36.7±16.6) mmHg vs. (36.2±17.5) mmHg, P=0.893). Conclusion: Favorable safety and efficacy are evidenced in patients with severely stenotic BAV undergoing TAVR with domestic prostheses. 目的: 评估使用国产瓣膜行经导管主动脉瓣置换术(TAVR)治疗二叶式主动脉瓣(BAV)重度狭窄的安全性和有效性。 方法: 本研究是前瞻性、单中心、非随机对照研究。连续入选2016年1月至2020年4月在空军军医大学第一附属医院心内科使用国产瓣膜行TAVR治疗的症状性重度主动脉瓣狭窄(AS)患者,按瓣叶形态分为BAV组与三叶式主动脉瓣(TAV)组,比较两组基线特征、手术资料,主要终点为术后1个月的全因死亡率。 结果: 共纳入100例患者,年龄为(69.8±8.9)岁,男性71例(71%)。其中BAV组51例,TAV组49例。与TAV组比较,BAV组患者的年龄小[(67.1±8.6)岁比(72.7±8.4)岁,P=0.002],近端升主动脉直径宽[(39.7±5.7)mm比(36.0±4.2)mm,P<0.001],(美国)胸外科医师协会死亡风险预测评分(STS-PROM)低[3.1(1.9,5.4)%比5.9(2.6,12.3)%,P=0.002]。术中,BAV组与TAV组植入瓣中瓣的比例分别为15.7%(8/51)、18.4%(9/49)(P=0.721),中重度瓣周漏发生率分别为2.0%(1/51)、0(P=1.000),器械成功率分别为82.4%(42/51)、81.6%(40/49)(P=0.925)。BAV组与TAV组术后1个月全因死亡率分别为2.0%(1/51)、10.2%(5/49)(P=0.108)。超声心动图结果显示BAV组术后平均跨瓣压差(PGmean)高于TAV组[13.0(10.0,16.0)mmHg比9.0(7.0,14.0)mmHg,P=0.003](1 mmHg=0.133 kPa),但PGmean下降值(较术前)两组差异无统计学意义[(36.7±16.6)mmHg比(36.2±17.5)mmHg,P=0.893]。 结论: 使用国产瓣膜行TAVR治疗BAV重度狭窄具有良好的安全性和有效性。.
引用
- Sun Q, Wang B, Zhu CJ, et al. [Evaluation of the safety and efficacy of transcatheter aortic valve replacement with domestic prostheses for patients with severely stenotic bicuspid aortic valve]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 33706459. doi:10.3760/cma.j.cn112148-20200902-00698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。